企庭中国民营经济网
导航菜单
←返回首页

Lingang Signs Healthcare MOU in Seoul, Clarifying Cross-Border Path for Private Firms

作者:企庭AI研究院9 阅读
Lingang Signs Healthcare MOU in Seoul, Clarifying Cross-Border Path for Private Firms
On September 21, 2026, the "Invest Shanghai, Share the Future" overseas event in Seoul concluded with Lingang New Area signing a technology and industry MOU with Korea's Logit Healthcare. This signals a new opening for private firms seeking cross-border collaboration.
  • Lingang signs healthcare MOU with Korean firm
  • China-Korea Torch Innovation Park boosts tech transfer
  • Dewu deepens cross-border supply chain ties

1. Seoul Stop: Lingang Adds Another Cross-Border Deal

According to a September 22, 2026 announcement on the Lingang New Area Management Committee's official website, the "Invest Shanghai, Share the Future" overseas series (Seoul stop) was successfully held on September 21 local time. Shanghai Vice Mayor Lu Shan delivered the keynote presentation. Bao Xuhui, Minister of the Chinese Embassy in Korea; Kim Hyun-woo, Director-General of the Seoul Metropolitan Government's Economic Office; and Lee Dong-geun, Executive Vice Chairman of the Korea Enterprises Federation, attended and spoke. Wu Xiaohua, Deputy Secretary of the Lingang New Area Party Working Committee, gave a special presentation on Lingang's industrial development. The event aimed to showcase new foreign investment opportunities in Shanghai, promote the latest financial opening policies, and deepen two-way investment and industrial collaboration between Shanghai and Korea.

Among the outcomes from the Seoul stop, Lingang New Area signed a technology and industry cooperation MOU with Korea's Logit Healthcare, explicitly targeting high-quality development in the pharmaceutical sector. This move extends Lingang's logic in biomedicine: using institutional innovation to lower barriers for cross-border technology collaboration, and using industrial space to host international R&D and commercialization. For private firms watching Lingang, this means the international cooperation channel in healthcare is becoming more concrete and actionable.

2. From Single Deals to Systemic Synergy: Reading Three Outcomes

The Seoul stop was not a single-project signing but a multi-layered arrangement spanning technology, capital, and supply chains. Beyond Lingang's MOU with Logit Healthcare, the China-Korea Torch Innovation Park signed an MOU with the Korea Innovation Center in China to promote cross-border matching and industrialization of high-tech achievements. Dewu Information Group signed an MOU with Korea's Anlian International to deepen practical collaboration in cross-border business, product supply, supply chain coordination, and data cooperation.

Each track has its own focus. The Lingang management committee level drives industrial policy and park platform alignment. The China-Korea Torch Innovation Park focuses on cross-border transformation of tech achievements. Dewu approaches from the consumer end, targeting cross-border goods and supply chain coordination. Together, they sketch a shift from point-to-point investment promotion to systemic synergy. Lingang's role is not merely a recipient but a testing ground for regulatory alignment and factor allocation.

Shanghai and Seoul are both core East Asian cities with complementary industrial strengths and a solid trade and economic foundation. Shanghai reviewed the deep cooperation base with Korea and emphasized its continued advantage as a city with "five centers" and composite functions, alongside ongoing efforts to optimize the investment environment. For private firms, such city-level frameworks often mean more stable expectations—when intergovernmental communication mechanisms mature, the cost of trial and error at the enterprise level tends to fall.

3. Implications for Private Firms: Treat Cross-Border Cooperation as Capacity Building

The Seoul signings appear to be government-enterprise MOUs, but on a deeper level they represent a stress test of Lingang's cross-border industrial synergy. Private firms can read at least three signals.

First, cross-border technology cooperation in healthcare is gaining institutional support. Lingang's deal with Logit Healthcare shows that international cooperation in pharma has moved from trade to technology and industry. Private firms with expertise in medical devices, digital health, or health services should watch Lingang's arrangements for cross-border R&D, data flows, and talent introduction.

Second, cross-border matching of high-tech achievements now has a clearer channel. The MOU between the China-Korea Torch Innovation Park and the Korea Innovation Center in China points to "cross-border matching and industrialization." Private firms can consider how to plug in: as technology recipients, as commercialization operators, or as supply chain partners. The value of a channel lies in structuring previously scattered cross-border resources.

Third, cross-border supply chain coordination remains the most accessible entry point. Dewu's cooperation with Anlian International covers cross-border business, product supply, supply chain coordination, and data cooperation—areas familiar to private firms. Lingang's cross-border trade facilitation policies and data flow pilots can serve as levers for optimizing supply chain layouts.

Conclusion: The Seoul event has ended, but the MOUs signed between Lingang and Korean partners need time to materialize. For private firms, the key is not chasing the heat of every signing but understanding the institutional logic behind it—Lingang is turning cross-border cooperation from an occasional event into a systemic capability. As that capability accumulates, going global becomes less about fighting alone and more about having a platform and rules to rely on.

Source: Lingang New Area Management Committee official website (lingang.gov.cn).

最新